Abstract
The development of ligands for the A3 adenosine receptor (AR) has been directed mainly by traditional medicinal chemistry, but the influence of structure-based approaches is increasing. Rhodopsin-based homology modeling had been used for many years to obtain three-dimensional models of the A3AR, and different A3AR models have been published describing the hypothetical interactions with known A3AR ligands having different chemical scaffolds. The recently published structure of the human A2AAR provides a new template for GPCR modeling, however even use of the A2AAR as a template for modeling other AR subtypes is still imprecise. The models compared here are based on bovine rhodopsin, the human β2-adrenergic receptor, and the A2AAR as templates. The sequence of the human A3AR contains only one cysteine residue (Cys166) in the second extracellular loop (EL2), which putatively forms a conserved disulfide bridge with the respective cysteine residues of TM3 (Cys83). Homology models of the A3AR have been helpful in providing structural hypotheses for the design of new ligands. Site-directed mutagenesis of the A3AR shows an important role in ligand recognition for specific residues in TM3, TM6 and TM7.
Current Pharmaceutical Design
Title: Human A3 Adenosine Receptor as Versatile G Protein-Coupled Receptor Example to Validate the Receptor Homology Modeling Technology
Volume: 15 Issue: 35
Author(s): Erika Morizzo, Stephanie Federico, Giampiero Spalluto and Stefano Moro
Affiliation:
Abstract: The development of ligands for the A3 adenosine receptor (AR) has been directed mainly by traditional medicinal chemistry, but the influence of structure-based approaches is increasing. Rhodopsin-based homology modeling had been used for many years to obtain three-dimensional models of the A3AR, and different A3AR models have been published describing the hypothetical interactions with known A3AR ligands having different chemical scaffolds. The recently published structure of the human A2AAR provides a new template for GPCR modeling, however even use of the A2AAR as a template for modeling other AR subtypes is still imprecise. The models compared here are based on bovine rhodopsin, the human β2-adrenergic receptor, and the A2AAR as templates. The sequence of the human A3AR contains only one cysteine residue (Cys166) in the second extracellular loop (EL2), which putatively forms a conserved disulfide bridge with the respective cysteine residues of TM3 (Cys83). Homology models of the A3AR have been helpful in providing structural hypotheses for the design of new ligands. Site-directed mutagenesis of the A3AR shows an important role in ligand recognition for specific residues in TM3, TM6 and TM7.
Export Options
About this article
Cite this article as:
Morizzo Erika, Federico Stephanie, Spalluto Giampiero and Moro Stefano, Human A3 Adenosine Receptor as Versatile G Protein-Coupled Receptor Example to Validate the Receptor Homology Modeling Technology, Current Pharmaceutical Design 2009; 15 (35) . https://dx.doi.org/10.2174/138161209789824777
DOI https://dx.doi.org/10.2174/138161209789824777 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research C-Peptide and its Correlation to Parameters of Insulin Resistance in the Metabolic Syndrome
CNS & Neurological Disorders - Drug Targets Cognitive Therapy for Schizophrenia: Treatment and Dissemination
Current Pharmaceutical Design Postmortem-Assessed Impairment of Neuronal Activity in Depression: The Dominant Impact of Suicide
CNS & Neurological Disorders - Drug Targets Ceramide-Based Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Cognitive Processes in Alcohol Binges: A Review and Research Agenda
Current Drug Abuse Reviews Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point
Current Drug Targets Zinc in the Glutamatergic Theory of Depression
Current Neuropharmacology The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimer’s Disease
Current Pharmaceutical Design Drug-Mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex
Current Medicinal Chemistry Editorial [Hot Topic: Recent Advances and Future Prospect in Protease Targeting (Executive Editor: B. Turk) ]
Current Pharmaceutical Design Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Real Time Analysis of Neurotransmitters in the Brain Using a Micro-Electrode System
Current Neurovascular Research Renal Heat Shock Proteins Over-Expression Due to Anabolic Androgenic Steroids Abuse
Mini-Reviews in Medicinal Chemistry Biomarkers for Alzheimer's Disease Diagnosis
Current Alzheimer Research Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism Chronic Inflammatory Disorders and Accelerated Atherosclerosis: Chronic Kidney Disease
Current Pharmaceutical Design Role of Dietary Polyphenols in Attenuating Brain Edema and Cell Swelling in Cerebral Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design Cerebral Malaria - A Neurovascular Pathology with Many Riddles Still to be Solved
Current Neurovascular Research